Skip to content
The San Francisco

Bay Area biotech's groundbreaking blood test to detect 50+ cancers gets critical FDA panel approval

Bay Area biotech's groundbreaking blood test to detect 50+ cancers gets critical FDA panel approval
Photo: KTVU FOX 2 News · view original

A Bay Area biotech company appears to be one major step closer to receiving final federal approval for its groundbreaking multi-cancer early detection (MCED) test, designed to screen for more than 50 types of cancer with a simple blood draw.

Sources and story details